Discussion
PONV, vomiting
ADVERSE EVENTS
Our trial compared the incidence of PONV between remimazolam-remifentanil and remimazolam-alfentanil in hysteroscopy. Based on our data, remimazolam-remifentanil causes less PONV than remimazolam-alfentanil in hysteroscopy.During the period of this study, we did not observe any serious side effects in either patient group or side effects requiring withdrawal from this study. The incidence of PONV in Group RR (2/102, 2.0%) was significantly lower than that in Group RA (12/102, 11.8%) (p < 0.05). There was no significant difference in the incidence of adverse events, such as low SpOIn previous research by Yi et al., the incidence of PONV in the PACU after anaesthesia with remimazolam combined with alfentanil reached 50% [Remimazolam is a new ultra–short-acting benzodiazepine and has the advantages of a rapid onset, high clearance rate (1.14 L/min), and metabolic process that is independent of liver and kidney function [Previous studies have compared the incidence of PONV between remifentanil and alfentanil [There are some limitations to this study. This was a single-centre investigation, which limited the statistical analysis of the two groups of patients. Because remimazolam is a newly marketed drug, to ensure the safety of patients, we selected populations with low risk when designing the inclusion criteria for the trial, and the conclusion should be interpreted with caution. Additionally, we only evaluated the occurrence of PONV in the PACU and did not evaluate the occurrence of PONV within 24 h after surgery. Our main concern in this study was the incidence of PONV, but we did not record arbitrary values on a numerical rating scale (NRS) ranging from 0 (“everything okay”) to 10 (“vomiting”) to assess the degree of PONV [